MYCN

[Nature Communications] Scientists analyzed the MYCN amplicon structure using short-read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and Hi-C. This reveals two distinct classes of amplicons which explain the regulatory requirements for MYCN overexpression.

[Science Translational Medicine] The authors used human tumor organoids representing multiple MYCN-amplified high-risk neuroblastomas to perform a high-throughput drug screen with approved or emerging oncology drugs.

[Genes & Development] To study roles for MYCN amplification in small cell lung cancer (SCLC) progression and chemoresistance, we developed a genetically engineered mouse model of MYCN-overexpressing SCLC.

[Cellular Oncology] Investigators found that Bruton’s tyrosine kinase was highly expressed in primary neuroblastoma samples, preferentially in MYCN-amplified neuroblastoma cases, and was associated with a poor prognosis.